Clinical Study

More Favorable Metabolic Impact of Three-Times-Weekly versus Daily Growth Hormone Treatment in Naïve GH-Deficient Children

Alessandro Ciresi, Floriana Cicciò, Stefano Radellini, Valentina Guarnotta, Anna Maria Calcataerra, and Carla Giordano

Section of Endocrinology, Biomedical Department of Internal and Specialist Medicine (DIBIMIS), University of Palermo, Palermo, Italy

Correspondence should be addressed to Carla Giordano; carla.giordano@unipa.it

Received 23 February 2017; Revised 14 April 2017; Accepted 26 April 2017; Published 28 May 2017

Academic Editor: Dario Iafusco

Copyright © 2017 Alessandro Ciresi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. To evaluate whether two different regimens of weekly injections could lead to similar auxological and metabolic effects in children with growth hormone deficiency (GHD).

Design. 32 GHD children (25 males, mean age 10.5 ± 2.2 yr) were randomly assigned to receive daily (group A, 16 patients) or TIW (group B, 16 patients) GHT for 12 months.

Methods. Auxological parameters, insulin-like growth factor-I (IGF-I), glucose and insulin during OGTT, glycosylated hemoglobin (HbA1c), lipid profile, the oral disposition index (DIo), the homeostasis model assessment estimate of insulin resistance (Homa-IR), and the insulin sensitivity index (ISI).

Results. After 12 months, both groups showed a significant and comparable improvement in height (p < 0.001) and IGF-I (p < 0.001). As regards the metabolic parameters, in both groups, we found a significant increase in fasting insulin (p < 0.001 and p = 0.026) and Homa-IR (p < 0.001 and p = 0.019). A significant increase in fasting glucose (p = 0.001) and a decrease in ISI (p < 0.001) and DIo (p = 0.002) were only found in group A.

Conclusions. The TIW regimen is effective and comparable with the daily regimen in improving auxological parameters and has a more favorable metabolic impact in GHD children. This trial is registered with ClinicalTrials.gov NCT03033121.

1. Introduction

Children with acclaimed GH deficiency (GHD) should be treated with recombinant human GH with the primary objective of the normalization of height and attainment of normal adult stature. In addition, the metabolic and body composition benefits should always be considered. Long-term GHT should theoretically mimic the complex physiological pattern of GH release, which is unlikely to be achieved with the current modes of administration. From 1960, GH treatment (GHT) in hypopituitary children was restricted for many years to three injections per week (TIW), because it was convenient and efficacious [1]. The availability of recombinant GH has enabled larger scale use of GHT on a daily basis. Indeed, daily subcutaneous injections were found to be more effective for children and this daily format was introduced as a routine treatment regimen during the 1980s [2]. Currently, GHT in GHD patients is commonly administered in daily injections [3], but this modality of treatment is not complied with by the totality of patients. In addition, it should be considered that physiological spontaneous pulsatile GH secretion cannot be reproduced by either TIW or daily injections and that a perfect physiological regimen has not been identified. The role played by GH pulsatility on both growth and metabolism is important, although it is not known whether closer imitation of the endogenous GH secretory pattern would improve the response to GHT [4]. For these reasons, efforts have been made to make GHT more similar to physiological GH secretion and long-acting forms of recombinant human GH with a more convenient dosing regimen are under development for children and adults [5–7].
In addition, the effectiveness of any therapy is contingent on patient adherence and the reported levels of nonadherence to GHT in children are highly variable, leading to reduced efficacy and increased health care costs [8–11]. Since one of the main factors associated with poor adherence to GHT is the complex treatment regimen, reduced frequency of the administration of medication is generally associated with better adherence [12]. The clinical outcomes of daily versus TIW GH administration were already studied many years ago. The TIW regimen seems to produce similar effects to those of daily injections in both adults and children with GHD [13–15], although several studies have reported that the daily GH administration in children was more effective than TIW dosing on linear growth [16, 17]. However, to date, the metabolic effects of GHT given in an alternative regimen in GHD patients have only been evaluated in adults and never in children. This study aimed to reevaluate whether the same weekly dose of GH given by two different regimens of weekly injections could lead to similar auxological and especially metabolic effects in children with GHD.

2. Subjects and Methods

Thirty-two prepubertal children (25 males, 7 females; mean age 9.5 ± 2.2 years) with a diagnosis of isolated idiopathic GHD were consecutively enrolled in this prospective randomized clinical study over a period going from January 2015 to December 2015 from the Section of Endocrinology, University of Palermo (www.ClinicalTrials.gov, identification number NCT03033121).

All subjects and their parents gave informed written consent to the study. The diagnosis of GHD was established by the clinical, auxological, radiological, and biochemical criteria of the GH Research Society [3].

As auxological data, we considered the height and growth velocity 1 year before diagnosis. As radiological criteria, we considered a bone age delay, estimated from an X-ray of the left wrist and hand and evaluated according to the criteria of the GH Research Society [3].

As auxological data, we considered the height and growth velocity 1 year before diagnosis. As radiological criteria, we considered a bone age delay, estimated from an X-ray of the left wrist and hand and evaluated according to the criteria of the GH Research Society [3]. Subsequently, we calculated the bone/chronological age ratio.

Biochemically, GHD was demonstrated by the failure of GH to respond to the two stimuli (arginine and glucagon) in a 1 : 1 ratio to two different GHT regimens, given in the evening: group A included 16 children (12 males, 4 females, mean age 9.8 ± 2.2 years) receiving daily GH injections, and group B included 16 children (13 males, 3 females, mean age 9.3 ± 2.2 years) receiving TIW of GH.

All children were naïve to GHT. In line with our internal protocol, in all children, we used a weight-based GH treatment [20]. Regardless of GH peak, we used the same initial weekly dose of 0.175 mg/kg (corresponding to the daily dose of 0.025 mg/kg) of GH with a gradual increase every 6 months in order to maintain the IGF-I levels constantly in the normal range. In detail, from months 1 to 6, we used the mean weekly dose of 0.175 mg/kg and from months 6 to 12, the mean weekly dose of 0.20 mg/kg.

Four children (3 males, 1 female; 2 from group A and 2 from group B, resp.) who changed pubertal stage (from the first to the second stage) during the follow-up were excluded from the study.

2.1. Study Design. In all patients, at baseline and after 12 months of GHT, we measured the body height (standard deviation, SD), body mass index (BMI), and waist circumference (WC). The height and BMI were expressed as SD due to the wide age range of patients.

Blood samples were drawn after an overnight fast. Laboratory assessment included fasting glucose and insulin levels, insulin-like growth factor-I (IGF-I), glycosylated hemoglobin (HbA1c), lipid profile including total cholesterol, high-density cholesterol (HDL), and triglycerides. Low-density lipoprotein (LDL) cholesterol levels were evaluated by the following formula: total cholesterol – (HDL cholesterol – triglycerides/5). This sample also served as the baseline sample for an oral glucose tolerance test (OGTT). Blood samples were collected every 30 min for 2 h for glucose and insulin measurements. At 12 months, in group B, all samples were drawn the morning after the GH dose was received.

The estimation of the basal insulin secretion included fasting insulin levels, while the oral disposition index (DIo) was used as an index of the ability of the β-cell to regulate its insulin response to stimuli based on the differences in insulin sensitivity. DIo was calculated at the times 0′ and 30′ during OGTT as described [21]. As surrogate estimates of insulin sensitivity, we considered the homeostasis model assessment estimate of insulin resistance (Homa-IR) [22] and the insulin sensitivity index (ISI), a composite index derived from the OGTT and validated by Matsuda and DeFronzo [23].

The institutional Ethics Committee of the University of Palermo approved this study. At the time of hospitalization, a written informed consent for the scientific use of the data was obtained from all the participants’ parents.

2.2. Hormone and Biochemical Assays. All biochemical data were collected after an overnight fasting. Glucose, HbA1c, and lipids were measured in the centralized accredited laboratories of the University of Palermo with the standard methods. Serum insulin was measured by ELISA (DRG Instruments GmbH, Germany). The sensitivity of the method was 1 IU/mL. The normal insulin range (IU/mL)
Table 1: Clinical and biochemical features of patients grouped according to the GH treatment regimen (group A and group B) at baseline and after 12 months of treatment.

|                          | 7 doses per week | 7 doses per week | 3 doses per week | 3 doses per week |
|--------------------------|------------------|------------------|------------------|------------------|
|                          | (group A)        | (group A)        | (group B)        | (group B)        |
|                          | 16 patients      | 16 patients      | 16 patients      | 16 patients      |
|                          | baseline         | 12 months        | baseline         | 12 months        |
| Mean ± SD                | Mean ± SD        | Mean ± SD        | Mean ± SD        | Mean ± SD        |
| **Height (SD)**          | −2.06 ± 0.43     | −1.5 ± 0.40      | <0.001           | −2.04 ± 0.69     | −1.5 ± 0.50      | <0.001           |
| **BMI (SD)**             | −0.46 ± 0.48     | −0.45 ± 1.3      | 0.876            | −0.79 ± 0.45     | −0.86 ± 0.8      | 0.052            |
| **Waist circumference (cm)** | 60.5 ± 10.4     | 62 ± 10          | 0.317            | 60.1 ± 9.0       | 61.5 ± 7.0       | 0.463            |
| **Growth velocity (SD)** | −3.4 ± 0.9       | 2.7 ± 1.7        | 0.003            | −3.3 ± 0.9       | 3 ± 1.4          | <0.001           |
| **Bone/chronological age ratio** | 0.81 ± 0.12     | 0.90 ± 0.05      | 0.089            | 0.81 ± 0.09      | 0.89 ± 0.11      | 0.098            |
| **IGF-I (μg/L)**         | 99.5 ± 23.8      | 332 ± 125        | <0.001           | 100 ± 23.4       | 352 ± 89.1       | <0.001           |

SD: standard deviation; BMI: body mass index.

was 5–19. Throughout the follow-up, serum GH levels were measured by immunoradiometric assay using commercially available kits (Radim, Italy). The sensitivity of the assay was 0.04 μg/L. The intra- and interassay coefficients of variation (CVs) were 2.5–3.9 and 3.8–5.0%, respectively. We reported GH concentrations in μg/L of IS 98/574.

IGF-I levels were measured by a chemiluminescent immunometric assay (Immulite 2000; Diagnostic Products Corp., Los Angeles, CA) using murine monoclonal anti-IGF-I antibodies. The standards were calibrated against the World Health Organization second IS 87/518. The assay had an analytical sensitivity of 1.9 μg/L. The intra- and interassay CVs were 2.3–3.9% and 3.7–8.1%, respectively.

2.3. Statistical Analysis. The Statistical Packages for Social Sciences (SPSS) version 17 was used for data analysis. Baseline characteristics were presented as mean ± standard deviation (SD); rates and proportions were calculated for categorical data. The normality of distribution of the quantitative variables was assessed with the Kolmogorov-Smirnov test. The differences between groups were evaluated by the Student t-test. A p value of <0.05 was considered statistically significant.

3. Results

The baseline clinical and biochemical features of children, grouped according to the different GHT regimens, are shown in Table 1.

No difference was found for chronological age (9.8 ± 2.2 versus 9.3 ± 2.2 years; p = 0.553), height (−2.06 ± 0.43 versus −2.04 ± 0.69 SD; p = 0.332), growth velocity (−3.4 ± 0.9 versus −3.3 ± 0.9 SD; p = 0.418), BMI (−0.46 ± 0.48 versus −0.79 ± 0.45 SD; p = 0.418), WC (60.5 ± 10.4 versus 60.1 ± 9.0 cm; p = 0.828), and bone age delay (0.81 ± 0.12 versus 0.81 ± 0.09; p = 0.053) between groups A and B. Similarly, the 2 groups of children showed similar IGF-I levels (99.5 ± 23.8 versus 100 ± 23.4 μg/L) and GH peak after arginine (5.08 ± 2.54 versus 3.28 ± 2.49 μg/L; p = 0.062) and glucagon test (3.22 μg/L ± 1.96 μg/L versus 4.77 μg/L ± 3.31 μg/L; p = 0.119).

Table 2: Difference in metabolic parameters between patients grouped according to the GH treatment regimen (group A and group B) at baseline.

|                          | 7 doses per week | 3 doses per week |
|--------------------------|------------------|------------------|
|                          | (group A)        | (group B)        |
|                          | 16 patients      | 16 patients      |
| Mean ± SD                | Mean ± SD        | Mean ± SD        |
| **Fasting glucose** (mmol/L) | 4 ± 0.65        | 4.17 ± 0.45      | 0.801           |
| **Fasting insulin** (IU/mL) | 2.9 ± 2.2       | 2.8 ± 2.2        | 0.687           |
| **HbA1c (%)**            | 5.1 ± 0.3        | 5.3 ± 0.3        | 0.108           |
| **Homa-IR**              | 0.52 ± 0.41      | 0.53 ± 0.41      | 0.688           |
| **ISI-Matsuda**          | 9.65 ± 0.82      | 9.03 ± 1.63      | 0.186           |
| **DLo**                  | 4.48 ± 1.81      | 4.68 ± 1.39      | 0.548           |
| **Total cholesterol** (mmol/L) | 4.12 ± 0.76     | 3.98 ± 0.51      | 0.130           |
| **HDL cholesterol** (mmol/L) | 1.58 ± 0.44     | 1.65 ± 0.31      | 0.563           |
| **LDL cholesterol** (mmol/L) | 2.84 ± 0.53     | 2.11 ± 0.36      | 0.063           |
| **Triglycerides** (mmol/L) | 1.50 ± 0.41     | 1.38 ± 0.52      | 0.942           |

BMI: body mass index; DLo: oral disposition index.

After 12 months of treatment, both groups of children showed a significant increase in height (−1.5 ± 0.40 versus −2.06 ± 0.43 SD and −1.5 ± 0.5 versus −2.04 ± 0.69 SD; both p < 0.001), growth velocity (2.7 ± 0.7 versus −3.4 ± 0.9 SD; p = 0.003 and 3 ± 1.4 versus −3.3 ± 0.9 SD; p < 0.001), and IGF-I levels (332 ± 125 versus 99.5 ± 23.8 μg/L and 352 ± 89.1 versus 100 ± 23.4 μg/L; both p < 0.001), with a concomitant lower, although not statistically significant, bone age delay (0.90 ± 0.05 versus 0.81 ± 0.12; p = 0.089 and 0.89 ± 0.11 versus 0.81 ± 0.09; p = 0.098), while no significant difference was found in BMI and WC (Table 1).

As regards the metabolic parameters, no difference was found in baseline parameters between the 2 groups.
Table 2). After 12 months of treatment in both groups, we found a significant increase in fasting insulin (9.2 ± 5.4 versus 2.9 ± 2.2 IU/mL; p < 0.001 and 5.7 ± 2.4 versus 2.8 ± 2.2 IU/mL; p = 0.026) and Homa-IR (1.98 ± 1.20 versus 0.52 ± 0.41 IU/mL; p < 0.001 and 1.16 ± 0.53 versus 0.53 ± 0.41; p = 0.019). A significant increase in fasting glucose (4.77 ± 0.39 versus 4 ± 0.65 mmol/L; p = 0.001) with a concomitant decrease in ISI-Matsuda (8.59 ± 0.83 versus 9.65 ± 0.82; p < 0.001) and Dlo (2.46 ± 1.27 versus 4.48 ± 1.81; p = 0.002) from baseline to 12 months was only found in group A (Figure 1; Table 3).

No significant changes were found in either group in HbA1c levels and lipid profile (Table 3).

When we analyzed the change (delta) in clinical and metabolic parameters from baseline to 12 months of GHT, we found a significantly greater delta of insulin (p = 0.043), Homa-IR (p = 0.032), ISI-Matsuda (p < 0.001), and Dlo (p = 0.001) in group A than in group B. The delta in fasting glucose and HbA1c, although not statistically significant, was found to be higher in group A than group B, while no significant difference was found in clinical parameters and in other metabolic indexes (Table 4). No side effects were observed in any child.

### 4. Discussion

This prospective and controlled study demonstrates that TIW regimen of GHT has comparable auxological effects to daily treatment with a more favorable metabolic impact, leading to a less pronounced worsening in insulin sensitivity and beta-cell secretion.

It is known that the classical GHT, consisting of a single daily GH injection, does not correspond to physiological spontaneous GH secretion and probably leads to continuous exposure and supraphysiological 24-hour integrated concentrations of GH. In addition, GH pulsatility reveals two major attributes, pulse amplitude and pulse frequency, and several studies have demonstrated that auxological parameters in children are mainly modulated by GH pulse amplitude, while frequency appears to play a smaller role [24, 25]. Clinical studies that have compared the TIW regimen with the daily administration of GH in children have always evaluated almost exclusively the auxological data, although the goal of GHT is also metabolic. Several studies report that the daily GH administration was more effective on linear growth than TIW dosing [2, 14, 16, 17, 26]. These data were confirmed by MacGillivray et al., who demonstrated greater growth...
velocity in prepubertal naïve GHD children after 4 years of GHT given daily rather than thrice weekly [27]. In our study, in line with previous studies, we found comparable auxological effects with the two GHT regimens, since all children showed a significant increase in height and growth velocity, without any difference in the delta of these parameters from baseline to 12 months of GHT in the two groups of children. These results are in agreement with the study of Smith et al., who demonstrated no difference in auxological parameters after 12 months of GHT in GHD children receiving GH three or six days a week or twice daily six days a week, assessing the main role played by the GH dose and not by the regimen of administration [14]. Similar results were shown a few years later by Cavallo et al., who observed no difference in auxological parameters during the 3 times/week treatment schedule started during the follow-up in already treated GHD children compared to the previous 6 times/week schedule [15]. The comparable auxological effect of the 2 regimens of GHT has also been demonstrated in patients with Turner syndrome earlier by Cavallo et al., who observed no difference in surgical parameters during the 3 times/week treatment schedule compared to the previous 6 times/week schedule [14]. Similar results were shown a few years later by Cavallo et al., who observed no difference in auxological parameters during the 3 times/week treatment schedule started during the follow-up in already treated GHD children compared to the previous 6 times/week schedule [15]. The comparable auxological effect of the 2 regimens of GHT has also been demonstrated in patients with Turner syndrome earlier by Cavallo et al., who observed no difference in surgical parameters during the 3 times/week treatment schedule compared to the previous 6 times/week schedule [14].

Table 3: Metabolic parameters of patients grouped according to the GH treatment regimen (group A and group B) at baseline and after 12 months of treatment.

| Parameter                        | 7 doses per week (group A) | 7 doses per week (group B) | 3 doses per week (group A) | 3 doses per week (group B) |
|----------------------------------|---------------------------|---------------------------|---------------------------|---------------------------|
|                                  | Mean ± SD                 | Mean ± SD                 | Mean ± SD                 | Mean ± SD                 |
| Fasting glucose (mmol/L)        | 4.0 ± 0.65                | 4.77 ± 0.39               | 4.17 ± 0.45               | 4.51 ± 0.35               |
| Fasting insulin (IU/mL)         | 2.9 ± 2.2                 | 9.2 ± 5.4                 | 2.8 ± 2.2                 | 5.7 ± 2.4                 |
| HbA1c (%)                       | 5.1 ± 0.3                 | 5.2 ± 0.3                 | 5.3 ± 0.3                 | 5.2 ± 0.2                 |
| Homa-IR                         | 0.52 ± 0.41               | 1.98 ± 1.20               | 0.53 ± 0.41               | 1.16 ± 0.53               |
| ISI-Matsuda                     | 9.65 ± 0.82               | 8.59 ± 0.83               | <0.001 9.03 ± 1.63        | 8.81 ± 1.57               |
| DIo                              | 4.48 ± 1.81               | 2.46 ± 1.27               | 4.68 ± 1.39               | 4.49 ± 1.30               |
| Total cholesterol (mmol/L)      | 4.12 ± 0.76               | 4.07 ± 0.78               | 3.98 ± 0.51               | 3.87 ± 0.58               |
| HDL cholesterol (mmol/L)        | 1.58 ± 0.44               | 1.54 ± 0.44               | 1.65 ± 0.31               | 1.86 ± 0.45               |
| LDL cholesterol (mmol/L)        | 2.84 ± 0.53               | 2.84 ± 0.55               | 2.11 ± 0.36               | 1.95 ± 0.61               |
| Triglycerides (mmol/L)          | 1.50 ± 0.41               | 1.54 ± 0.61               | 1.38 ± 0.52               | 1.22 ± 0.30               |

DIo: oral disposition index.

Table 4: Change (delta) in clinical and metabolic parameters from baseline to 12 months of GH treatment of patients grouped according to the GH treatment regimen.

| Parameter                        | 7 doses per week (group A) | 7 doses per week (group B) | 3 doses per week (group A) | 3 doses per week (group B) |
|----------------------------------|---------------------------|---------------------------|---------------------------|---------------------------|
|                                  | Mean ± SD                 | Mean ± SD                 | Mean ± SD                 | Mean ± SD                 |
| Delta height (SD)                | 0.5 ± 0.3                 | −0.4 ± 0.6                | 0.5 ± 0.2                 | 0.092                     |
| Delta BMI (SD)                   | 0.03 ± 0.6                | −0.4 ± 0.6                | 0.109                     |                           |
| Delta waist circumference (cm)   | 1.4 ± 4.4                 | 1.4 ± 4.8                 | 0.223                     |                           |
| Delta growth velocity (SD)       | 5.2 ± 1.7                 | 6.3 ± 2.7                 | 0.945                     |                           |
| Delta IGF-I (μg/L)               | 220.5 ± 112.7             | 204.8 ± 70.9              | 0.210                     |                           |
| Delta fasting glucose (mmol/L)   | 0.78 ± 0.76               | 0.34 ± 0.32               | 0.175                     |                           |
| Delta fasting insulin (IU/mL)    | 6.3 ± 4.2                 | 2.9 ± 3.4                 | 0.043                     |                           |
| Delta HbA1c (%)                  | 0.07 ± 0.1                | −0.05 ± 0.1               | 0.078                     |                           |
| Delta Homa-IR                    | 1.46 ± 0.99               | 0.63 ± 0.70               | 0.032                     |                           |
| Delta ISI-Matsuda                | −1.06 ± 0.43              | −0.21 ± 0.19              | <0.001                    |                           |
| Delta DIo                        | −1.31 ± 0.97              | −0.37 ± 0.34              | 0.001                     |                           |
| Delta total cholesterol (mmol/L) | 0.06 ± 0.01               | 0.08 ± 0.05               | 0.941                     |                           |
| Delta HDL cholesterol (mmol/L)   | 0.04 ± 0.03               | −0.12 ± 0.04              | 0.209                     |                           |
| Delta LDL cholesterol (mmol/L)   | 0.01 ± 0.01               | 0.15 ± 0.04               | 0.498                     |                           |
| Delta triglycerides (mmol/L)     | 0.04 ± 0.03               | 0.13 ± 0.05               | 0.392                     |                           |

BMI: body mass index; DIo: oral disposition index.
in both groups, in line with other studies [29, 30], and they reinforce the idea of the noninferior clinical efficacy of TIW treatment compared to daily treatment.

Conversely, the metabolic effects of GHT given in an alternative regimen have been evaluated in adult patients and never in children. It is well known that severe GHD in children is associated with significant impairment of body composition and an adverse metabolic profile [31], as well as in adults [32].

Amato et al. showed that GHT with TIW regimen in adult GHD patients is effective in improving metabolic parameters, with an efficacy comparable to that observed in patients treated with daily GHT [29], and these data are in agreement with those of Giavoli et al. [33]. Reinforcing these findings, Pincelli et al. demonstrated that a TIW regimen of GHT is able to reverse cardiovascular abnormalities in addition to improving body composition and lipid profile in adult patients [34].

Substantially, our data demonstrated that all children, regardless of GHT regimen, showed a worsening in insulin sensitivity after 12 months of treatment, as demonstrated by the increase in Homa-IR, already shown in adult patients [33]. This effect of the GHT is well known. Indeed, given the insulin antagonist action of GH in addition to the direct stimulatory effect on β-cell, GHT can lead to glucose metabolism impairment through a decrease in insulin sensitivity and an impairment of pancreatic β-cell function [35]. We previously demonstrated an increase in Homa-IR, related to the increased insulin levels, in GHD children after GHT [36, 37], and a degree of impairment of glucose metabolism during GHT has often been previously demonstrated [38]. However, the limit of the evaluation of the insulin sensitivity and secretion performed through insulin-derived indexes [39] is always to be taken into account.

As regards the change in glucose levels during GHT, in adult GHD patients, Johansson et al. demonstrated lower blood glucose and insulin levels during a TIW regimen than during daily injections [40]. The authors explained this result as due to the concomitant lower serum IGF-I levels, which may be important for the balanced effect of GH on insulin sensitivity and glucose metabolism [41].

Our data partially support this study. We only found a significant increase in fasting glucose levels in group A, despite the concomitant increase in insulin during GHT in both groups. This result suggests the inability of the β-cells to adequately compensate the insulin resistance state, as indicated by the significant reduction in Dl0 and ISI-Matsuda, only in group A. This finding is in agreement with a previous study that demonstrated inadequate β-cell compensation of decreased insulin sensitivity in GHD children during GHT [42].

In addition, confirming these data, when the change in metabolic parameters from baseline to 12 months of GHT was evaluated and directly compared in the 2 groups of children, group A showed a significantly greater decrease in insulin sensitivity and β-cell function than group B, with a concomitant greater increase in fasting glucose, although not statistically significant.

Probably, GHT using daily injections may not be optimal with respect to glucose metabolism because of the relative continuous exposure of GH. Furthermore, constant GH exposure might theoretically downregulate the GH receptor. Conversely, GHD children treated with the TIW regimen, because of the relatively short half-life of GH, have lower circulating GH during the “off” days and the more distinct peaks of GH could lead to a more favorable metabolic impact. Indeed, the lower metabolic effects should be advantageous for insulin sensitivity and, consequently, for fasting glucose levels, which did not significantly increase. However, the stable Hba1c levels indicate that there was no difference in long-term glucose homeostasis between the two regimens of GHT. This finding is in agreement with the data of Johansson et al., who showed comparable Hba1c levels in GHD adults after 8 weeks of GHT with TIW or daily regimen [40].

In addition, the current study shows no significant difference in lipid profile between the 2 groups of patients, in agreement with the study of Lucidi et al., who previously demonstrated that GHT given TIW-induced increments in protein synthesis and lipolysis comparable to those obtained after daily treatment GHT in adult patients [30].

On the other hand, GHT given as a TIW regimen could theoretically result in better patient compliance than daily injections and this point is relevant considering the need for long-term treatment [40]. However, we could not evaluate this issue because of the lack of the use of specific questionnaires for the assessment of quality of life or adherence to therapy, which is a limitation of our study. Other limitations of this study may be related to the small size of the population and the short-term follow-up. Indeed, although the best auxological benefits generally occur during the first year of treatment, a longer follow-up may be useful to have more reliable data. In addition, data on body composition measured by dual-energy X-ray absorptiometry as a marker of metabolic risk might be useful, but they are available for a minority of patients.

However, the discrepancies among the various studies are due to the high variability of the patients enrolled (i.e., the majority of the studies have enrolled children not naïve to GHT but already treated with GH for a different length of time), to different doses of GH used or different duration of the follow-up. To avoid these limits, our study was designed to enroll only GHD children naïve to GHT and consecutively admitted in a controlled way. To better understand whether the two regimens of GHT lead to different metabolic outcomes, we believe that these data must be validated in additional larger prospective studies with longer follow-up. Indeed, the duration of 12 months may be probably too short to fully define the metabolic impact of the two different modalities of treatment and these data should be considered as preliminary data.

In conclusion, our study confirmed that GHT with the TIW injections regimen is effective in improving auxological parameters and that the auxological efficacy of this regimen is comparable with that of a daily regimen. This regimen proved to have at least similar auxological effects to daily treatment, and it could theoretically ensure higher acceptance of treatment in children, in addition to having
demonstrated for the first time a more favorable metabolic impact in GHD children. Therefore, the TIW injection regimen could represent an effective alternative to the conventional daily regimen during the first 1 year of GHT and can be favorably applied in the treatment of GHD children.

Conflicts of Interest

There is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

References

[1] S. D. Frasier, “Human pituitary growth hormone (hGH) therapy in growth hormone deficiency,” Endocrine Reviews, vol. 4, no. 2, pp. 155–170, 1983.

[2] K. W. Kastrup, J. S. Christiansen, J. K. Andersen, and H. Orskov, “Increased growth rate following transfer to daily sc administration from three weekly im injections of hGH in growth hormone deficient children,” Acta Endocrinologica, vol. 104, no. 2, pp. 148–115, 1983.

[3] Growth Hormone Research Society, “Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. GH Research Society,” The Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 11, pp. 3990–3993, 2000.

[4] C. J. Strasburger and W. Kiess, “Which route of growth hormone administration serves best? An invited commentary,” European Journal of Endocrinology, vol. 135, no. 3, pp. 289–290, 1996.

[5] C. Höybye, A. F. Pfeiffer, D. Ferone et al., “A phase 2 trial of long-acting TransCon growth hormone in adult GH deficiency,” Endocr Connect, vol. 6, no. 3, pp. 129–138, 2017.

[6] C. J. Strasburger, P. Vanuga, J. Payer et al., “MOD-4023, a long-acting carboxy-terminal peptide-modified human growth hormone: results of a phase 2 study in growth hormone-deficient adults,” European Journal of Endocrinology, vol. 176, no. 3, pp. 283–294, 2017.

[7] W. V. Moore, H. J. Nguyen, G. B. Kletter et al., “A randomized safety and efficacy study of Somavaratan (VRS-317), a long-acting rhGH, in pediatric growth hormone deficiency,” The Journal of Clinical Endocrinology and Metabolism, vol. 101, no. 3, pp. 1091–1097, 2016.

[8] F. Haverkamp, L. Johansson, H. Dumas et al., “Observations of nonadherence to recombinant human growth hormone therapy in clinical practice,” Clinical Therapeutics, vol. 30, no. 2, pp. 307–316, 2008.

[9] B. G. Fisher and C. L. Acerini, “Understanding the growth hormone therapy adherence paradigm: a systematic review,” Hormone Research in Pediatrics, vol. 79, no. 4, pp. 189–196, 2013.

[10] R. G. Rosenfeld and B. Bakker, “Compliance and persistence in pediatric and adult patients receiving growth hormone therapy,” Endocrine Practice, vol. 14, no. 2, pp. 143–154, 2008.

[11] W. S. Cutfield, J. G. Derraik, A. J. Gunn et al., P. L. Hofman et al., “Non-compliance with growth hormone treatment in children is common and impairs linear growth,” PloS One, vol. 6, no. 1, article e16223, 2011.

[12] J. Y. Reginster, V. Rabenda, and A. Neuprez, “Adherence, patient preference and dosing frequency: understanding the relationship,” Bone, vol. 38, no. 4, Supplement 1, pp. 52–56, 2006.

[13] S. M. Orme, J. P. Sebastian, B. Oldroyd et al., “Comparison of measures of body composition in a trial of low dose growth hormone replacement therapy,” Clinical Endocrinology, vol. 37, no. 5, pp. 453–459, 1992.

[14] P. J. Smith, P. C. Hindmarsh, and C. G. Brook, “Contribution of dose and frequency of administration to the therapeutic effect of growth hormone,” Archives of Disease in Childhood, vol. 63, no. 5, pp. 491–494, 1988.

[15] L. Cavallo, F. De Luca, S. Bernasconi, T. Arrigo, R. Gurrado, and C. Zecchino, “The effect of different growth hormone administration frequencies on growth in growth hormone-deficient patients,” Hormone Research, vol. 49, Supplement 2, pp. 73–77, 1998.

[16] P. C. Hindmarsh, R. Stanhope, M. A. Preece, and C. G. Brook, “Frequency of administration of growth hormone—an important factor in determining growth response to exogenous growth hormone,” Hormone Research, vol. 33, Supplement 4, pp. 83–89, 1990.

[17] B. Boersma, B. Rikken, and J. M. Wit, “Catch-up growth in early treated patients with growth hormone deficiency. Dutch Growth Hormone Working Group,” Archives of Disease in Childhood, vol. 72, no. 5, pp. 427–431, 1995.

[18] M. Anderson, “Use of the Greulich-Pyle Radiographic Atlas of Skeletal Development of the Hand and Wrist in a clinical context,” American Journal of Physical Anthropology, vol. 35, no. 3, pp. 347–352, 1971.

[19] W. A. Marshall and J. M. Tanner, “Variations in pattern of pubertal changes in girls,” Archives of Disease in Childhood, vol. 44, no. 235, pp. 291–303, 1969.

[20] A. Grimberg, S. A. DiVall, C. Polychronakos et al., “Murad MH; Drug and Therapeutics Committee and Ethics Committee of the Pediatric Endocrine Society. Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency,” Hormone Research in Pediatrics, vol. 86, no. 6, pp. 361–397, 2016.

[21] K. M. Utzschneider, R. L. Pigeon, M. V. Faulenbach et al., “Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels,” Diabetes Care, vol. 32, no. 2, pp. 335–341, 2009.

[22] D. R. Matthews, J. P. Hosker, A. S. Rudenski, B. A. Naylor, D. F. Treacher, and R. C. Turner, “Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man,” Diabetologia, vol. 28, no. 7, pp. 412–419, 1985.

[23] M. Matsuda and R. A. DeFronzo, “Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp,” Diabetes Care, vol. 22, no. 9, pp. 1462–1470, 1999.

[24] N. Mauras, R. M. Blizzard, K. Link, M. L. Johnson, A. D. Rogol, and J. D. Veldhuis, “Augmentation of growth hormone secretion during puberty: evidence for a pulse amplitude-modulated phenomenon,” The Journal of Clinical Endocrinology and Metabolism, vol. 64, no. 3, pp. 596–601, 1987.

[25] K. Albertsson-Wikland and S. Rosberg, “Analyses of 24-hour growth hormone profiles in children: relation to growth,” The Journal of Clinical Endocrinology and Metabolism, vol. 67, no. 3, pp. 493–500, 1988.
[26] S. L. Blethen, P. Compton, B. M. Lippe, R. G. Rosenfeld, G. P. August, and A. Johanson, “Factors predicting the response to growth hormone (GH) therapy in prepubertal children with GH deficiency,” The Journal of Clinical Endocrinology and Metabolism, vol. 76, no. 3, pp. 574–579, 1993.

[27] M. H. MacGillivray, J. Baptista, and A. Johanson, “Outcome of a four-year randomized study of daily versus three times weekly somatropin treatment in prepubertal naïve growth hormone-deficient children. Genentech Study Group,” The Journal of Clinical Endocrinology and Metabolism, vol. 81, no. 5, pp. 1806–1809, 1996.

[28] G. Massa, B. J. Otten, S. M. de Muinck Keizer-Schrama et al., “Treatment with two growth hormone regimens in girls with Turner syndrome: final height results. Dutch Growth Hormone Working Group,” Hormone Research, vol. 43, no. 4, pp. 144–146, 1995.

[29] G. Amato, G. Mazziotti, C. Di Somma et al., “Recombinant growth hormone (GH) therapy in GH-deficient adults: a long-term controlled study on daily versus thrice weekly injections,” The Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 10, pp. 3720–3725, 2000.

[30] P. Lucidi, S. Laureti, S. Santoni et al., “Administration of recombinant human growth hormone on alternate days is sufficient to increase whole body protein synthesis and lipolysis in growth hormone deficient adults,” Clinical Endocrinology, vol. 52, no. 2, pp. 173–179, 2000.

[31] P. Matusik, M. Klesiewicz, K. Klos et al., “Baseline body composition in prepubertal short stature children with severe and moderate growth hormone deficiency,” International Journal of Endocrinology, vol. 2016, Article ID 4563721, p. 6, 2016.

[32] L. Giovannini, G. Tirabassi, G. Muscogiuri, C. Di Somma, A. Colao, and G. Balercia, “Impact of adult growth hormone deficiency on metabolic profile and cardiovascular risk,” Endocrine Journal, vol. 62, no. 12, pp. 1037–1048, 2015.

[33] C. Giavoli, V. Cappiello, S. Porretti et al., “Growth hormone therapy in GH-deficient adults: continuous vs alternate-days treatment,” Hormone and Metabolic Research, vol. 35, no. 9, pp. 557–561, 2003.

[34] A. I. Pincelli, R. Bragato, M. Scacchi et al., “Three weekly injections (TWI) of low-dose growth hormone (GH) restore low normal circulating IGF-I concentrations and reverse cardiac abnormalities associated with adult onset GH deficiency (GHD),” Journal of Endocrinological Investigation, vol. 26, no. 5, pp. 420–428, 2003.

[35] N. Møller, P. C. Butler, M. A. Antsiferov, and K. G. Alberti, “Effects of growth hormone on insulin sensitivity and forearm metabolism in normal man,” Diabetologia, vol. 32, no. 2, pp. 105–110, 1989.

[36] A. Ciresi, M. C. Amato, A. Criscimanna et al., “Metabolic parameters and adipokine profile during GH replacement therapy in children with GH deficiency,” European Journal of Endocrinology, vol. 156, no. 3, pp. 353–360, 2007.

[37] A. Ciresi, F. Ciccio, M. C. Amato, and C. Giordano, “Reevaluation of the clinical and metabolic behavior of children with isolated growth hormone deficiency during GH treatment according to newly proposed note 39 of the Italian Medicines Agency (AIFA),” Journal of Endocrinological Investigation, vol. 38, no. 12, pp. 1301–1307, 2015.

[38] D. Capalbo, G. Mattace Raso, A. Esposito et al., “Cluster of cardiometabolic risk factors in children with GH deficiency: a prospective, case-control study,” Clinical Endocrinology, vol. 80, no. 6, pp. 856–862, 2013.

[39] A. Ciresi, F. Ciccio, S. Radellini, and C. Giordano, “Utility of C-peptide for a reliable estimate of insulin secretion in children with growth hormone deficiency,” Growth Hormone & IGF Research, vol. 29, pp. 71–77, 2016.

[40] J. O. Johansson, L. Wirén, J. Oscarsson, B. A. Bengtsson, and G. Johansson, “Growth hormone (GH) replacement in GH-deficient adults: a crossover trial comparing the effect on metabolic control, well-being and compliance of three injections per week versus daily injections,” Growth Hormone & IGF Research, vol. 13, no. 6, pp. 306–315, 2003.

[41] M. A. Hussain, O. Schmitz, J. S. Christiansen, J. Zapf, and E. R. Froesch, “Metabolic effects of insulin-like growth factor-I: a focus on insulin sensitivity,” Metabolism, vol. 44, no. 10, Supplement 4, pp. 108–112, 1995.

[42] A. Ciresi, M. C. Amato, and C. Giordano, “Reduction in insulin sensitivity and inadequate β-cell capacity to counteract the increase in insulin resistance in children with idiopathic growth hormone deficiency during 12 months of growth hormone treatment,” Journal of Endocrinological Investigation, vol. 38, pp. 351–359, 2015.